+Vote!
Business Wire (Free subscription) | 24/11/2009
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen® Technology, today announced that President and Chief Executive Officer, Michael V. Novinski, will present a corporate overview at the 13th Annual Biotech & Specialty...
+Vote!
GuruFocus Updates (Free subscription) | 09/11/2009
By 10qk. Emisphere Technologies Inc. ( EMIS ) filed Quarterly Report for the period ended 2009-09-30. Read more » »
+Vote!
Business Wire (Free subscription) | 09/11/2009
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB: EMIS) today announced financial and operational results for the third quarter and nine months ended September 30, 2009. THIRD QUARTER FINANCIAL RESULTS For the three months ended September 30, 2009, Emisphere reported a net loss of $4.0 million, or $0.11 per basic and diluted share, compared to a net loss of $5.1 million,...
3Vote!
Business Wire (Free subscription) | 05/11/2009
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Company’s Board of Directors effective immediately. Mr. Rothwell’s appointment fills the vacancy created by Franklin Berger, who recently resigned from the Board in order to focus more time on certain...
+Vote!
Business Wire (Free subscription) | 04/11/2009
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company’s financial and operational results for the third quarter ended September 30, 2009 on Monday, November 9, 2009 at 10:00 AM EST. A press release will be issued prior to market open. The live webcast of the conference call can be...
3Vote!
Business Wire (Free subscription) | 02/11/2009
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTC BB:EMIS) today announced that interim data from an ongoing study demonstrated its high-dose oral Eligen® B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency. Normal levels of serum B12 and active B12 were achieved by 100 percent of those study participants who have...
+Vote!
Medical News Today (Free subscription) | 04/11/2009
Emisphere Technologies, Inc. (OTC BB:EMIS) announced that interim data from an ongoing study demonstrated its high-dose oral Eligen® B12 (1000mcg) performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency.
+Vote!
Medical News Today (Free subscription) | 16/10/2009
Emisphere Technologies, Inc. (OTCBB: EMIS) announced study results in which twice-daily oral salmon calcitonin using Emisphere's proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis.
+Vote!
Business Wire (Free subscription) | 15/10/2009
CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (OTCBB: EMIS) announced study results in which twice-daily oral salmon calcitonin using Emisphere’s proprietary Eligen® Drug Delivery Technology significantly suppressed markers of cartilage and bone degradation versus placebo in men and women with osteoarthritis, the most common form of arthritis. The study, a Phase...
